Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros). The transaction has been approved by the boards of directors of both companies, the Saturday announcement said. Inhibitex has been focusing on development of nucleotide medicines designed for treatment of hepatitis C. Its lead product under development, known as INX-189, has displayed potent antiviral abilities, experts said. \"The acquisition of Inhibitex builds on Bristol-Myers Squibb\'s long history of discovering, developing and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,\" Lamberto Andreotti, chief executive officer of Bristol-Myers Squibb, said in a statement. \"There is significant unmet medical need in hepatitis C,\" he added. \"This acquisition represents an important investment in the long-term growth of the company.\" Russell Plumb, president and CEO of Inhibitex, said the transaction puts INX-189 and his company\'s other assets in the hands of an organization that can \"more optimally develop them.\" Bristol-Myers Squibb will finance the acquisition, which is expected to be completed in about a month, from its existing cash resources, officials said.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor